OncoMatch/Clinical Trials/Leukemia — Chronic Lymphocytic (CLL)
Leukemia — Chronic Lymphocytic (CLL) Clinical Trials
OncoMatch filters Leukemia — Chronic Lymphocytic (CLL) trials by the molecular markers that determine eligibility — TP53, IGHV, BTK, SF3B1, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Leukemia — Chronic Lymphocytic (CLL) trials
These are the molecular markers most commonly required or evaluated in Leukemia — Chronic Lymphocytic (CLL) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Leukemia — Chronic Lymphocytic (CLL) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Merck Sharp & Dohme LLC
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Children's Oncology Group
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Loxo Oncology, Inc.
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
How OncoMatch finds Leukemia — Chronic Lymphocytic (CLL) trials for you
AI reads the protocol
Every Leukemia — Chronic Lymphocytic (CLL) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Leukemia — Chronic Lymphocytic (CLL) and mark your biomarker results — TP53, IGHV, BTK — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.